{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:58:06Z","timestamp":1785423486518,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["AA\/18\/2\/34218"],"award-info":[{"award-number":["AA\/18\/2\/34218"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","award":["NIHR203326"],"award-info":[{"award-number":["NIHR203326"]}],"id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.rpth.2024.102628","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:27:33Z","timestamp":1731688053000},"page":"102628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Andexanet\u00a0alfa: trials just leave us with more questions"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2738-6236","authenticated-orcid":false,"given":"Richard J.","family":"Buka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102628_bib5","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet\u00a0alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102628_bib6","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1161\/STROKEAHA.120.030565","article-title":"Hemostatic efficacy and anti-FXa (factor Xa) reversal with andexanet\u00a0alfa in intracranial hemorrhage: ANNEXA-4 substudy","volume":"52","author":"Demchuk","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102628_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.annemergmed.2019.05.034","article-title":"FDA approval of andexanet\u00a0alfa based on a single-arm trial: if there is a villain, who is it?","volume":"74","author":"Pallin","year":"2019","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.rpth.2024.102628_bib8","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102628_bib9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMc2407378","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"391","author":"Yate","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102628_bib10","first-page":"773","article-title":"Andexanet for Factor Xa Inhibitor\u2013Associated Acute Intracerebral Hemorrhage","volume":"391","author":"Wong","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102628_bib11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMc2407378","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"391","author":"Kreutziger","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102628_bib12","article-title":"Validation of the National Institutes of Health Stroke Scale in intracerebral hemorrhage","volume":"3","author":"Dusenbury","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102628_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.04.012","article-title":"What change in the National Institutes of Health Stroke Scale should define neurologic deterioration in acute ischemic stroke?","volume":"22","author":"Siegler","year":"2013","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.rpth.2024.102628_bib14","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1161\/STROKEAHA.120.032487","article-title":"Predicting 90-day outcome after thrombectomy: baseline-adjusted 24-hour NIHSS Is more powerful than NIHSS score change","volume":"52","author":"Mistry","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102628_bib15","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2024.102628_bib16","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.3324\/haematol.2017.174037","article-title":"Catalytically inactive Gla-domainless factor Xa binds to TFPI and\u00a0restores ex\u00a0vivo coagulation in hemophilia plasma","volume":"102","author":"Ersayin","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102628_bib17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2017007112","article-title":"Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet\u00a0alfa","volume":"1","author":"Siegal","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102628_bib18","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102628_bib19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.STR.24.7.987","article-title":"Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality","volume":"24","author":"Broderick","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102628_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-023-00424-7","article-title":"Intracerebral haemorrhage","volume":"9","author":"Puy","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rpth.2024.102628_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.STR.28.1.1","article-title":"Early hemorrhage growth in patients with intracerebral hemorrhage","volume":"28","author":"Brott","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102628_bib22","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa0707534","article-title":"Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage","volume":"358","author":"Mayer","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102628_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(08)70069-3","article-title":"Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial","volume":"7","author":"Anderson","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2024.102628_bib24","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(18)31033-X","article-title":"Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial","volume":"391","author":"Sprigg","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102628_bib25","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1056\/NEJMoa1214609","article-title":"Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage","volume":"368","author":"Anderson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102628_bib26","first-page":"379","article-title":"On the 12th day of Christmas, a statistician sent to me","volume":"20","author":"Riley","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102628_bib27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1212\/WNL.0b013e3182143317","article-title":"Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes","volume":"76","author":"Dowlatshahi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.rpth.2024.102628_bib28","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/STROKEAHA.122.041246","article-title":"Location-specific hematoma volume cutoff and clinical\u00a0outcomes in intracerebral hemorrhage","volume":"54","author":"Teo","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102628_bib29","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102628_bib30","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1603460","article-title":"Intensive blood-pressure lowering in patients with acute cerebral hemorrhage","volume":"375","author":"Qureshi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102628_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45183","article-title":"Meta-research: a comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals","volume":"8","author":"Herrera-Perez","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.rpth.2024.102628_bib32","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019003298","article-title":"PATCH trial: explanatory analyses","volume":"135","author":"Baharoglu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102628_bib33","article-title":"Update on andexanet\u00a0alfa for reversal of FXa inhibitors: Annexa-I trial","author":"Shoamanesh","year":"2024","journal-title":"AC Forum Webinar"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924003236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924003236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:16:00Z","timestamp":1762629360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924003236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2475037924003236"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102628","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Andexanet\u00a0alfa: trials just leave us with more questions","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102628"}}